Core Viewpoint - The English version of "Fantôme Rapport," a romantic horror mystery set on a ghostly luxury liner, is set to launch on January 16, 2026 [1] Group 1 - The narrative focuses on how bonds shape the fate of characters aboard the luxury liner [1]

Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics (NasdaqGM:RAPP) - **Industry**: Precision Neuroscience - **Focus**: Development of therapies for neurological conditions using receptor-associated proteins Key Points and Arguments Company Vision and Strategy - Rapport Therapeutics aims to be a leading precision neuroscience company, leveraging receptor-associated proteins to create highly specific compounds for various neurological conditions [8][9] - The company was formed through a collaboration between Third Rock and Johnson & Johnson, bringing significant institutional knowledge to its programs [9] Lead Program: RAP-219 - **Description**: RAP-219 is a novel forebrain-restricted TARP gamma-8 AMPA modulator targeting focal onset seizures [10][11] - **Financial Position**: As of September 30, 2025, the company had approximately $513 million, providing a cash runway into the second half of 2029 [10] - **Clinical Progress**: Positive phase two data for RAP-219 was released in September 2025, with plans to enter pivotal studies in Q2 2026 [10][13] Market Opportunities - **Focal Onset Seizures**: Approximately 1.8 million patients in the U.S. with a market opportunity of $15 billion [16] - **Primary Generalized Tonic-Clonic Seizures**: Around 800,000 patients with a $7 billion market opportunity [16] - **Bipolar Mania**: 1.5 million patients with a $40 billion market opportunity [16] - **Long-Acting Injectable (LAI)**: Expected to be the first of its kind in epilepsy, providing significant revenue potential [15][16] Clinical Data and Efficacy - **Phase 2A Trial Results**: - 71% median reduction in long episodes (electrographic seizures) [27] - 77.8% reduction in clinical seizures, with 72% of patients achieving a 50% reduction [28] - 24% of patients achieved clinical seizure freedom, a significant outcome compared to historical placebo rates [29] - **Tolerability**: The drug was well tolerated with a low discontinuation rate of 10% [30] Future Developments - **Bipolar Mania Study**: Expected data in the first half of 2027 [35] - **Long-Acting Injectable**: Expected to enter IND-enabling studies with initial human PK data anticipated in 2027 [34][35] - **Discovery Pipeline**: Focused on nicotinic receptors with promising candidates for chronic pain and migraine [39] Regulatory and Market Positioning - Rapport Therapeutics has received positive feedback from the FDA, allowing for accelerated development of RAP-219 [13][32] - The company is positioned to potentially lead in the market with a new mechanism of action and favorable safety profile compared to existing treatments [44][46] Additional Important Information - The company emphasizes the importance of addressing treatment-resistant patients, with 30%-40% of focal onset seizure patients being refractory to current medications [16][18] - The long-acting injectable formulation is expected to mitigate risks associated with missed doses, a significant concern for patients and caregivers [47][48] - The discovery platform aims to create a self-sustaining pipeline, moving beyond single-asset dependency [38] This summary encapsulates the key insights from the conference call, highlighting the strategic direction, clinical advancements, and market potential of Rapport Therapeutics and its lead program, RAP-219.

Core Insights - The U.S. Food and Drug Administration (FDA) has allowed Rapport Therapeutics to advance RAP-219 into registrational trials for focal onset seizures (FOS), with Phase 3 program initiation expected in Q2 2026 [1][4] - The company is expanding its epilepsy portfolio to include primary generalized tonic-clonic seizures (PGTCS) based on strong Phase 2a data [1][4] - Other pipeline programs, including a Phase 2 trial in bipolar mania and long-acting injectable development, are progressing [1][11] Clinical and Pipeline Updates - Rapport is prioritizing programs with the greatest potential for patient impact and long-term value, aiming for a strong milestone cadence throughout 2026 and beyond [3] - The Phase 2a data in FOS supports a multi-billion dollar market opportunity, with estimates suggesting a greater than $2 billion commercial opportunity in the U.S. if approved [4] - An open-label long-term safety trial for RAP-219 has been initiated, with initial data expected in H2 2026 [4] - The company plans to initiate a Phase 3 trial for RAP-219 in PGTCS in the first half of 2027 [4] Business Updates - The company ended Q3 with $513 million in cash, expected to fund operations into the second half of 2029 [12] - The FDA has lifted the clinical hold on the diabetic peripheral neuropathic pain (DPNP) trial, but the company is deferring further investment in this program to focus on the α6β4 program for chronic pain and migraine [11][12] - Rapport will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [12]

Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule medicines for central nervous system (CNS) disorders, aiming to address significant unmet needs in neurology and psychiatry [1][2] - The company has a focused portfolio and proprietary research to establish a competitive edge in the CNS therapeutics market [1] Product Pipeline - The lead candidate is RAP-219, targeting focal epilepsy and other CNS indications, with additional programs addressing chronic pain and hearing disorders [3] - Positive results from a phase 2a clinical trial for RAP-219 were reported in September 2025, leading to a share price increase [8] Financial Performance - Rapport Therapeutics reported a net loss of $26.9 million in Q3 2025, but held cash, cash equivalents, and short-term investments totaling $513 million, expected to sustain operations into the second half of 2029 [8] - As of November 14, 2025, shares were priced at $24.37, reflecting a 10.87% increase over the past year, although underperforming the S&P 500 by 1.0 percentage points [3] Investment Activity - Cormorant Asset Management increased its holding in Rapport Therapeutics by purchasing an additional 251,600 shares, raising its total position to 3,192,521 shares valued at $94.82 million [5][6] - This purchase increased Cormorant's stake by approximately $61.38 million, representing 6.54% of its assets under management [4][5]

Core Viewpoint - Rapport Therapeutics, a clinical-stage biotechnology company, is focused on developing small molecule precision medicines for neurological and psychiatric disorders and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1]. Company Overview - Rapport Therapeutics is dedicated to discovering and developing small molecule precision medicines specifically for patients with neurological or psychiatric disorders [3]. - The company's founders have made significant discoveries regarding receptor associated proteins (RAPs) in the brain, which underpin Rapport's RAP technology platform [3]. - The precision neuroscience pipeline includes the lead investigational drug, RAP-219, which targets a RAP expressed in specific brain regions, aiming to treat drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [3]. - Additional programs are in preclinical and late-stage discovery phases, focusing on chronic pain and hearing disorders [3].

Company Overview - Rapport Therapeutics, Inc. (RAPP) currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4] - The company has shown strong price performance, with shares up 9.03% over the past week and 14.97% over the past month, outperforming the Zacks Medical - Biomedical and Genetics industry, which is up 5% and 3.48% respectively [6] Price Performance - Over the past quarter, RAPP shares have risen 24.16%, and over the last year, they are up 44.18%, significantly outperforming the S&P 500, which has moved 6.25% and 14.29% respectively [7] - The average 20-day trading volume for RAPP is 361,157 shares, indicating a bullish trend as the stock is rising with above-average volume [8] Earnings Outlook - In the past two months, 4 earnings estimates for RAPP have moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$3.01 to -$2.79 [10] - For the next fiscal year, 4 estimates have also moved upwards with no downward revisions during the same period, indicating positive sentiment around the company's earnings potential [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, RAPP is positioned as a promising investment opportunity for those seeking stocks with potential for near-term growth [12]

Core Insights - Rapport Therapeutics announced new data from the Phase 2a trial of RAP-219, highlighting its early onset of action and consistent efficacy in treating drug-resistant focal onset seizures [1][2][3] Efficacy and Safety Data - RAP-219 showed a statistically significant 77.8% reduction in clinical seizures compared to baseline over the 8-week treatment period, with 24% of participants achieving seizure freedom [3] - The treatment was well-tolerated, with a low discontinuation rate of 10% and most adverse events being mild [3] Early Onset of Action - The drug demonstrated early clinical response with median percent reductions in long episodes (LEs) and clinical seizures consistently observed throughout the treatment period [5][6] - Median percent reduction in LEs was 74.7% for both the first and second halves of the treatment, and 71.0% overall [6] Robust Efficacy Across Disease Severity - RAP-219 provided consistent responses regardless of baseline disease severity, with 85.7% of patients with lower baseline LE frequency achieving a ≥30% reduction in LE frequency [7] - Seizure freedom rates were similar across different baseline clinical seizure frequencies, indicating broad efficacy [7] Improvements in Quality of Life - Treatment with RAP-219 improved seizure intensity, recovery time, concentration ability, and reduced seizure interference with daily activities, suggesting potential enhancements in patients' quality of life [8][9] Future Development Plans - The company plans to hold an end-of-Phase 2 meeting with the FDA and anticipates initiating two pivotal Phase 3 trials in Q3 2026 [2] - Rapport is also developing a long-acting injectable formulation of RAP-219 to improve patient adherence [16] Broader Applications - Beyond epilepsy, RAP-219 is being evaluated in a Phase 2 trial for bipolar mania, with topline results expected in early 2027 [17]

Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shares have increased by 9.5% in the last four weeks, closing at $29.43, with a potential upside of 75% based on Wall Street analysts' mean price target of $51.5 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $13.2, indicating variability among analysts [2] - The lowest estimate suggests a 15.5% increase from the current price, while the highest estimate indicates a potential upside of 171.8% [2] Analyst Sentiment - Analysts show a consensus that RAPP will report better earnings than previously estimated, which supports the expectation of a stock price increase [4][11] - The Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Implications - While the consensus price target may not be a reliable indicator of the extent of RAPP's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Insights - Rapport Therapeutics is set to present results from its Phase 2a trial of RAP-219 for focal onset seizures at the 2025 American Epilepsy Society Annual Meeting, highlighting new efficacy analyses and treatment effects [1][2]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [8]. - The company's lead investigational drug, RAP-219, is designed to selectively target TARPγ8, a receptor associated protein expressed in specific brain regions, potentially offering a differentiated profile compared to traditional neuroscience medications [7][8]. Clinical Trial Details - The Phase 2a trial of RAP-219 will present topline efficacy and safety data, including the drug's effects during the first month of treatment and its consistency in efficacy throughout the treatment period [2][4]. - Additional analyses will cover the impact of baseline disease severity on efficacy outcomes and the effect of RAP-219 on seizure severity [2][6]. Presentation Schedule - The company will host a dedicated Scientific Exhibit Room at the meeting, featuring multiple poster presentations on RAP-219's clinical program [4][5]. - Specific poster sessions are scheduled for December 7 and 8, 2025, detailing various aspects of RAP-219's efficacy and safety [5][6].

Rapport Therapeutics Conference Call Summary Company Overview - **Company**: Rapport Therapeutics - **Focus**: Precision neuroscience, specifically through receptor-associated proteins - **Lead Program**: RAP-219, a TARP8 AMPA modulator targeting focal onset seizures and bipolar mania [4][5] Key Points and Arguments Product Development and Milestones - **RAP-219**: Demonstrated a best-in-class profile in focal onset seizures with a robust efficacy and tolerability profile [5][8] - **Phase Two Results**: Showed over 70% reduction in seizures over an eight-week period, with 24% of patients achieving complete seizure freedom [9][11] - **FDA Meeting**: Scheduled for Q4 2025 to discuss end of phase two results and path forward for pivotal studies in 2026 [18][19] - **Bipolar Mania Study**: Ongoing evaluation of RAP-219 with expected data in 2027 [5][6] Market Opportunity - **Focal Onset Seizures**: Approximately 1.8 million patients in the U.S. with 30-40% being treatment-resistant, representing a $10 billion-$15 billion market [11][12] - **Polypharmacy Management**: RAP-219 aims to provide a novel mechanism of action with better tolerability compared to existing treatments [12][13] - **Long-Acting Injectable (LAI)**: Development underway, expected to be transformational for patients, with potential for once-monthly or quarterly dosing [15][33][34] Safety and Efficacy - **Tolerability Profile**: RAP-219 showed no severe adverse events, with most being mild or moderate, even among patients on multiple background anti-seizure medications [9][10] - **Long Half-Life**: RAP-219 has a half-life of over 18 days, which may help prevent breakthrough seizures if doses are missed [13][28] Future Data and Expectations - **Upcoming Data Releases**: Full trial results from phase two and open-label extension study expected in 2026 [6][27] - **Phase Three Design**: Standard design anticipated, focusing on seizure reduction and responder analysis [20][21] - **Bipolar Program Read-Through**: Positive implications for RAP-219's efficacy in treating acute mania due to its mechanism targeting glutamate pathways [37][38] Additional Important Insights - **Market Research**: Indicated that RAP-219 will be utilized by both epileptologists and general neurologists across various treatment lines [14] - **Patient Population**: Phase two study included heavily treated patients, suggesting robust efficacy in difficult-to-treat populations [24] - **Regulatory Strategy**: Ongoing discussions with the FDA to align on NDA submission requirements [19][36] This summary encapsulates the critical aspects of Rapport Therapeutics' conference call, highlighting the company's strategic direction, product development, market potential, and future expectations.